Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Company profile
Ticker
GLSI
Exchange
Website
CEO
Mr. Snehal S. Patel
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
IRS number
205473709
GLSI stock data
Analyst ratings and price targets
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
1 Nov 24
ARS
2023 FY
Annual report to shareholders
1 Nov 24
DEF 14A
Definitive proxy
1 Nov 24
EFFECT
Notice of effectiveness
18 Oct 24
S-3
Shelf registration
7 Oct 24
10-Q
2024 Q2
Quarterly report
14 Aug 24
D
$2.50 mm in equity, sold $2.50 mm, 1 investor
17 Jun 24
8-K
Entry into a Material Definitive Agreement
17 Jun 24
10-Q
2024 Q1
Quarterly report
20 May 24
NT 10-Q
Notice of late quarterly filing
15 May 24
Financial summary
| Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 7.22 mm | 7.22 mm | 7.22 mm | 7.22 mm | 7.22 mm | 7.22 mm |
| Cash burn (monthly) | (no burn) | 309.95 k | 887.13 k | 878.13 k | 349.28 k | 565.44 k |
| Cash used (since last report) | n/a | 1.30 mm | 3.72 mm | 3.68 mm | 1.46 mm | 2.37 mm |
| Cash remaining | n/a | 5.93 mm | 3.50 mm | 3.54 mm | 5.76 mm | 4.85 mm |
| Runway (months of cash) | n/a | 19.1 | 4.0 | 4.0 | 16.5 | 8.6 |
Institutional ownership, Q2 2024
11.0% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 35 |
| Opened positions | 29 |
| Closed positions | 1 |
| Increased positions | 1 |
| Reduced positions | 1 |
| 13F shares | Current |
|---|---|
| Total value | 17.49 bn |
| Total shares | 1.45 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Weiner Michael Guy | 429.69 k | $9.35 mm |
| BLK BlackRock | 308.91 k | $5.33 bn |
| Vanguard | 268.17 k | $4.63 bn |
| Geode Capital Management | 127.69 k | $2.20 bn |
| Credit Agricole S A | 87.00 k | $1.50 bn |
| STT State Street | 68.40 k | $1.18 bn |
| Renaissance Technologies | 36.90 k | $636.89 mm |
| NTRS Northern Trust | 24.32 k | $419.76 mm |
| Charles Schwab Investment Management | 18.45 k | $318.52 mm |
| Man Group Limited | 16.65 k | $287.38 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 26 Sep 24 | Snehal Patel | Common Stock | Buy | Acquire P | No | No | 14.63 | 1,500 | 21.95 k | 5,536,102 |
| 12 Aug 24 | Jaye Thompson | Common Stock | Buy | Acquire P | No | No | 13.85 | 800 | 11.08 k | 263,148 |
| 6 Aug 24 | Snehal Patel | Common Stock | Buy | Acquire P | No | No | 13.81 | 2,000 | 27.62 k | 5,534,602 |
| 5 Aug 24 | Snehal Patel | Common Stock | Buy | Acquire P | No | No | 13.18 | 5,500 | 72.49 k | 5,532,602 |
| 2 Aug 24 | Jaye Thompson | Common Stock | Buy | Acquire P | No | No | 15.15 | 1,000 | 15.15 k | 262,348 |